24/7 Market News Snapshot 02 May, 2025 – ReShape Lifesciences, Inc. Common Stock (NASDAQ:RSLS)

May 2, 2025

DENVER, Colo., 02 May, 2025 (www.247marketnews.com) – (Nasdaq:RSLS) are discussed in this article.
ReShape Lifesciences, Inc. (Nasdaq:RSLS) is currently generating considerable buzz in the market as its stock price surged by approximately 67.85% to $0.569, following a strong trading volume of 17.54 million shares. This bullish momentum suggests heightened investor interest, likely spurred by recent positive developments within the company, including the unveiling of a groundbreaking Diabetes Neuromodulation device at the 12th Annual Minnesota Neuromodulation Symposium.

At this major event, Dr. Jonathan J. Waataja, Director of Research at ReShape, presented compelling pre-clinical data showcasing the innovative device’s potential to address insulin-induced hypoglycemia. The study focused on Hypoglycemia Vagus Nerve Stimulation (HVNS), which effectively targets the sub-diaphragmatic posterior vagus nerve, rapidly elevating blood glucose levels during critical low episodes. This novel approach stands out not only for its efficacy but also for its avoidance of cardiac side effects common in traditional vagal stimulation treatments.

Dr. Waataja emphasized the technology’s role in overcoming a significant barrier in diabetes care, declaring, “Hypoglycemia presents a serious hurdle in diabetes care, and our technology is designed to provide a rapid, effective intervention.” The promising results demonstrated in pre-clinical swine models underline the potential of HVNS to enhance patient safety and comfort without impacting heart rate or other system functions negatively.

Paul F. Hickey, President and CEO of ReShape Lifesciences, underscored the importance of these advancements, asserting their commitment to developing this revolutionary therapy through collaboration with leading researchers and partners. As the company progresses with these innovative solutions, it aims to significantly redefine diabetes management and improve the quality of life for individuals living with the condition. Investors and analysts alike should monitor this evolving narrative, as ReShape Lifesciences positions itself at the forefront of metabolic health solutions.

Related news for (RSLS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.